Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$13.82 +5.5%	$14.42	$10.96 ▼ $32.97	$735.60M	2.28	1.46 million shs	1.78 million shs
CSTL Castle Biosciences	$23.56 +2.0%	$19.50	$14.59 ▼ $35.84	$669.80M	1.07	588,171 shs	233,004 shs
PNTG The Pennant Group	$24.29 +0.9%	$24.54	$21.18 ▼ $37.13	$832.25M	1.31	413,350 shs	246,192 shs
XGN Exagen	$9.67 -1.6%	$8.41	$2.38 ▼ $10.34	$216.30M	1.6	214,595 shs	93,466 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+5.50%	+1.17%	+5.50%	-29.20%	-50.07%
CSTL Castle Biosciences	+2.04%	-1.87%	+19.23%	+33.86%	-18.51%
PNTG The Pennant Group	+0.87%	+1.17%	+9.12%	-17.80%	-25.97%
XGN Exagen	-1.63%	-1.93%	+8.53%	+33.38%	+227.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$13.82 +5.5%	$14.42	$10.96 ▼ $32.97	$735.60M	2.28	1.46 million shs	1.78 million shs
CSTL Castle Biosciences	$23.56 +2.0%	$19.50	$14.59 ▼ $35.84	$669.80M	1.07	588,171 shs	233,004 shs
PNTG The Pennant Group	$24.29 +0.9%	$24.54	$21.18 ▼ $37.13	$832.25M	1.31	413,350 shs	246,192 shs
XGN Exagen	$9.67 -1.6%	$8.41	$2.38 ▼ $10.34	$216.30M	1.6	214,595 shs	93,466 shs

Analysts Agree—These Gold Picks Outshine the Rest

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+5.50%	+1.17%	+5.50%	-29.20%	-50.07%
CSTL Castle Biosciences	+2.04%	-1.87%	+19.23%	+33.86%	-18.51%
PNTG The Pennant Group	+0.87%	+1.17%	+9.12%	-17.80%	-25.97%
XGN Exagen	-1.63%	-1.93%	+8.53%	+33.38%	+227.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.57	Moderate Buy	$27.67	100.19% Upside
CSTL Castle Biosciences	2.89	Moderate Buy	$37.00	57.05% Upside
PNTG The Pennant Group	2.60	Moderate Buy	$34.40	41.62% Upside
XGN Exagen	3.00	Buy	$11.25	16.34% Upside

Current Analyst Ratings Breakdown

Latest XGN, PNTG, CDNA, and CSTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2025	PNTG The Pennant Group	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$40.00
8/27/2025	CSTL Castle Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/26/2025	CDNA CareDx	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform
8/14/2025	PNTG The Pennant Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$31.00 ➝ $29.00
8/8/2025	CDNA CareDx	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$19.00 ➝ $14.00
7/30/2025	XGN Exagen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$10.00
7/30/2025	XGN Exagen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $11.00
7/30/2025	XGN Exagen	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$12.00
7/23/2025	XGN Exagen	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/18/2025	CDNA CareDx	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $26.00
7/16/2025	PNTG The Pennant Group	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$32.00 ➝ $28.00

(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$333.79M	2.20	$1.44 per share	9.63	$7.06 per share	1.96
CSTL Castle Biosciences	$332.07M	2.06	$1.00 per share	23.47	$16.28 per share	1.45
PNTG The Pennant Group	$695.24M	1.21	$0.93 per share	26.12	$9.08 per share	2.68
XGN Exagen	$55.64M	3.82	N/A	N/A	$0.54 per share	17.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	$52.55M	$1.02	13.55	N/A	N/A	17.97%	18.03%	12.88%	11/3/2025 (Estimated)
CSTL Castle Biosciences	$18.25M	-$0.35	N/A	N/A	N/A	-2.73%	2.37%	2.03%	11/3/2025 (Estimated)
PNTG The Pennant Group	$22.56M	$0.78	31.14	27.60	1.98	3.36%	9.85%	4.04%	11/5/2025 (Estimated)
XGN Exagen	-$15.11M	-$0.89	N/A	N/A	N/A	-28.85%	-130.38%	-34.69%	11/11/2025 (Estimated)

Latest XGN, PNTG, CDNA, and CSTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CDNA CareDx	$0.12	-$0.16	-$0.28	-$0.16	$90.72 million	$90.51 million
8/4/2025	Q2 2025	CSTL Castle Biosciences	-$0.51	$0.15	+$0.66	$0.15	$71.53 million	$86.18 million
7/29/2025	Q2 2025	XGN Exagen	-$0.18	-$0.18	N/A	-$0.21	$16.25 million	$17.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
PNTG The Pennant Group	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	3.30	3.00
CSTL Castle Biosciences	0.02	6.85	6.69
PNTG The Pennant Group	0.11	1.21	1.21
XGN Exagen	1.06	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
CSTL Castle Biosciences	92.60%
PNTG The Pennant Group	85.88%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	4.40%
CSTL Castle Biosciences	6.50%
PNTG The Pennant Group	5.40%
XGN Exagen	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	53.23 million	50.89 million	Optionable
CSTL Castle Biosciences	540	29.01 million	27.12 million	Optionable
PNTG The Pennant Group	7,000	34.56 million	32.70 million	Optionable
XGN Exagen	220	22.00 million	19.23 million	Optionable

XGN, PNTG, CDNA, and CSTL Headlines

Recent News About These Companies

Exagen Inc. (NASDAQ:XGN) Short Interest Update

September 6 at 4:38 AM | marketbeat.com

Stonepine Capital Management LLC Sells 155,302 Shares of Exagen Inc. $XGN

August 26, 2025 | marketbeat.com

Short Interest in Exagen Inc. (NASDAQ:XGN) Expands By 52.8%

August 20, 2025 | marketbeat.com

Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Buy" by Brokerages

August 18, 2025 | marketbeat.com

Exagen Inc. to Participate in Third Quarter Investor Conferences

August 6, 2025 | gurufocus.com

Exagen Inc. to Participate in Third Quarter Investor Conferences

August 6, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Exagen (XGN)

August 2, 2025 | theglobeandmail.com

Exagen (XGN) Receives a Buy from Craig-Hallum

August 1, 2025 | theglobeandmail.com

Exagen Inc. Reports Record Revenue Amidst Growth Challenges

August 1, 2025 | theglobeandmail.com

Canaccord Genuity Sticks to Its Buy Rating for Exagen (XGN)

July 31, 2025 | theglobeandmail.com

XGN | Exagen Inc. Annual Cash Flow Statement | MarketWatch

July 31, 2025 | marketwatch.com

Keybanc Upgrades Exagen (XGN)

July 31, 2025 | msn.com

Exagen upgraded to Overweight from Sector Weight at KeyBanc

July 30, 2025 | msn.com

Exagen Q2 Revenue Jumps 14 Percent

July 29, 2025 | aol.comA

Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

July 29, 2025 | seekingalpha.com

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

July 29, 2025 | zacks.com

Exagen Inc. Reports Strong Q2 2025 Results

July 29, 2025 | globenewswire.com

Craig-Hallum Initiates Coverage of Exagen (XGN) with Buy Recommendation

July 25, 2025 | msn.com

Exagen Inc. (XGN): A Bull Case Theory

July 24, 2025 | msn.com

Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?

July 24, 2025 | zacks.com

TD Cowen Remains a Buy on Exagen (XGN)

July 23, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, PNTG, CDNA, and CSTL Company Descriptions

CareDx NASDAQ:CDNA

$13.82 +0.72 (+5.50%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$13.64 -0.18 (-1.30%)

As of 09/5/2025 07:12 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Castle Biosciences NASDAQ:CSTL

$23.56 +0.47 (+2.04%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$23.58 +0.02 (+0.06%)

As of 09/5/2025 05:21 PM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

The Pennant Group NASDAQ:PNTG

$24.29 +0.21 (+0.87%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$24.27 -0.02 (-0.08%)

As of 09/5/2025 05:51 PM Eastern

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Exagen NASDAQ:XGN

$9.67 -0.16 (-1.63%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$9.68 +0.01 (+0.05%)

As of 09/5/2025 05:48 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XGN, PNTG, CDNA, and CSTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XGN, PNTG, CDNA, and CSTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XGN, PNTG, CDNA, and CSTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, PNTG, CDNA, and CSTL Company Descriptions

CareDx NASDAQ:CDNA

Castle Biosciences NASDAQ:CSTL

The Pennant Group NASDAQ:PNTG

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XGN, PNTG, CDNA, and CSTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XGN, PNTG, CDNA, and CSTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XGN, PNTG, CDNA, and CSTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, PNTG, CDNA, and CSTL Company Descriptions

CareDx NASDAQ:CDNA

Castle Biosciences NASDAQ:CSTL

The Pennant Group NASDAQ:PNTG

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools